Spark co-founder Kathy High joins a longtime collaborator at AskBio, helping steer Bayer's gene therapy push
Kathy High has re-emerged in the gene therapy space just as unexpectedly as she left Spark Therapeutics close to a year ago.
On the surface, the circumstances are not unlike Spark, which was getting absorbed into Roche following a $4.3 billion buyout. High, 68, was credited for both steering Luxturna toward an approval for a rare inherited eye disease caused by mutations in the RPE65 gene, setting up gene therapy research in hemophilia A and leading a Phase I/II trial for hemophilia B.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.